Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:triptorelin
|
| gptkbp:activities |
gptkb:item
|
| gptkbp:brand |
Decapeptyl 11.25 mg
Decapeptyl 3.75 mg Decapeptyl Depot |
| gptkbp:clinical_trial |
oncology
pediatrics gynecology studied in phase III trials |
| gptkbp:contraindication |
pregnancy
breastfeeding hypersensitivity to triptorelin |
| gptkbp:dosage_form |
single-use vial
|
| gptkbp:duration |
varies by condition
|
| gptkbp:effective_date |
approved by various health authorities
|
| gptkbp:excretion |
primarily renal
|
| gptkbp:formulation |
injectable solution
|
| gptkbp:frequency |
monthly or quarterly
|
| https://www.w3.org/2000/01/rdf-schema#label |
Decapeptyl
|
| gptkbp:indication |
uterine fibroids
advanced prostate cancer hormone-sensitive cancers |
| gptkbp:ingredients |
gptkb:triptorelin
|
| gptkbp:interacts_with |
anticoagulants
other hormonal therapies |
| gptkbp:is_available_on |
prescription medication
|
| gptkbp:is_monitored_by |
hormone levels during treatment
|
| gptkbp:is_used_for |
treatment of prostate cancer
treatment of precocious puberty treatment of endometriosis |
| gptkbp:lifespan |
approximately 3 hours
|
| gptkbp:manager |
subcutaneous injection
|
| gptkbp:manufacturer |
gptkb:Ipsen
|
| gptkbp:marketed_as |
many countries worldwide
|
| gptkbp:pharmacokinetics |
long-acting formulation
|
| gptkbp:population |
adult males
adult females children with precocious puberty |
| gptkbp:price |
varies by region and insurance
|
| gptkbp:regulatory_compliance |
FDA approved
EMA approved TGA approved |
| gptkbp:shelf_life |
36 months
|
| gptkbp:side_effect |
headache
nausea injection site reactions hot flashes |
| gptkbp:social_structure |
gptkb:protein
|
| gptkbp:storage |
store in a refrigerator
|
| gptkbp:type_of_care |
important for treatment efficacy
|